Background: The high incidence of vascular and lymphatic metastasis is closely associated with poor prognosis and mortality in cancer. Finding effective inhibitors to prevent pathological angiogenesis and lymphangiogenesis relies on appropriate in vivo models. The chick embryo chorioallantoic membrane (CAM) is formed by the fusion of the chorion and allantois during embryonic development. Summary: In this context, we primarily summarize the changes in vascular and lymphatic vessel formation in tumors under the action of drugs using this model, providing a preclinical model basis for effective tumor inhibitors. Key Messages: Due to natural immunological defects, chick embryos accept various tissue and species transplants without immune response. The CAM model has been widely used in studying angiogenesis, antiangiogenesis, tumor growth, tumor metastasis, and drug efficacy. This review describes the use of CAM assays as a valuable method for testing the in vivo effects of drugs on vascular and lymphatic vessel formation before further investigating the effects of drugs on tumor vessels and lymphatic vessels in animal models.

Angiogenesis and lymphangiogenesis play significant roles in tumor metastasis and spread [1]. Drugs targeting angiogenetic cascades have been developed, approved, and become standard treatment for certain diseases [1]. For example, bevacizumab, targeting vascular endothelial growth factor (VEGF)-A and inhibiting angiogenesis, is approved for treating advanced stages of colorectal, ovarian, and lung cancers [2]. Clinical evidence shows tumor cell dissemination through lymphatic vessels is three to five times more likely than through blood vessels [3]. Hence, radical lymphatic vessels and lymph node resection have become standard in cancer treatment [4]. However, few therapeutic strategies exist to inhibit lymphangiogenesis (such as lymphatic-target therapeutics) in cancer or to modulate the lymphatics in chronic inflammation [5].

Establishing appropriate in vivo models is crucial for studying tumor-derived blood and lymphatic vessel growth and identifying new antiangiogenic or anti-lymphangiogenic drugs. Most preclinical models are expensive, time-consuming, require surgical expertise, and need ethics committee approval [6, 7]. The 3Rs principle (Russell and Burch’s principle) in animal experimentation recommends replacing, reducing, and refining methods to minimize suffering [8, 9]. In this context, the chick embryo chorioallantoic membrane (CAM) assay has been introduced as an alternative in vivo model. It has been used to investigate endothelial cell proliferation, migration, and differentiation [10, 11], extracellular matrix remodeling [12], tumor-induced angiogenesis and metastasis [3‒15], and pharmacological compound effects [13, 14]. The CAM model offers advantages like short experimental period, rapid growth, low cost, ease of handling and housing, and natural immune deficiency of chick embryos [15, 16]. Its transparent membrane provides real-time visualization of embryonic development and vessel growth [15, 16]. The extensive vascularization and accessibility of the CAM model make it an ideal platform for studying antiangiogenic or anti-lymphangiogenic molecules. Existing research shows its value in both angiogenesis and lymphangiogenesis studies [9, 17‒19]. This review discusses the morphological structure and physiology of the CAM model, vascular and lymphatic-related research, and outlines its potential for future research in oncology, plastic surgery, and tissue engineering.

The CAM consists of three layers: chorionic epithelium (ectoderm), mesenchyme (mesoderm), and allantoic epithelium (endoderm) [18, 20] (Fig. 1). The chorionic epithelium, composed of ectoderm and attached to the shell, primarily facilitates gas exchange [16]. The mesoderm, composed of vascular and stromal elements, serves as the foundation for the subsequent formation of the capillary plexus of the allantoic capillary network [16]. At embryonic day 3.5 (ED3.5), allantois development begins, and at ED4, the endodermal hind pushes out of the embryo’s body and enters the embryo’s outer body [16]. During ED4–10, the allantoic vesicle grows rapidly. During this time, the mesoderm of the allantoic and the mesodermal layer of the chorion begin to combine to form the CAM [16].

Fig. 1.

Structural diagram of chick embryo allantoic membrane model as a platform for cancer research.

Fig. 1.

Structural diagram of chick embryo allantoic membrane model as a platform for cancer research.

Close modal

This vascularized allantois and avascular chorion combination causes the CAM surface to rapidly expand from 6 cm2 on ED6 to 65 cm2 on ED14, providing a large surface for in vivo experimentation [21]. Chick embryos typically incubate for 21 days, but experimental research is often conducted before ED17, as they are not considered living animals and do not require ethical approval in most countries [22].

The CAMs rich vascularization provides nutrients for transplanted tumors and fosters tumor growth. Immature blood vessels begin sprouting on ED1 and grow rapidly before ED8, generating capillary tufts and facilitating gas exchange with the external environment [23]. Capillary density continues to proliferate rapidly until ED8–11, after which the proliferation decreases [23]. During ED14, the density of blood vessels remains constant and angiogenesis ceases [10, 12, 24]. At ED18, the chick development is nearly concluded and blood and lymphatic vessels of the CAM begin to degenerate [12].

The lymphatics on the CAM developed more slowly than the vascular vessels. Experiments with quail-chicken chimeras demonstrated that allantoic mesoderm differentiate into lymphatic vessels [18]. Lymphatic vessels are associated with veins, and the larger veins are surrounded by lymphatic plexus [25]. The lymphatics of CAM have dual origins. The lymphatic system is primarily endogenous, with portions originating from posterior lymph sacs [18]. The lymphatics on the CAM drain via the umbilicus lymphatic trunks, whereas the lymphatic vessels within the embryo drain via the thoracic duct to the subclavian vein [18]. The deep lymphatics (located near the large veins) appear at ED4–5, whereas the lymphangiogenesis on the CAM begins at ED5–9 [26]. The formation of lymphatic vessels is accompanied by the expansion of blood vessels and blind-ended sprouts [27]. Initially, isolated lymphatic endothelial progenitor cells gather at the tips of developing blood vessels. The lymphatics then expand and divide, followed by the expansion of the blood vessels [18]. At that time, the polarized mural progenitor cells express alpha-smooth muscle actin [27]. At ED15, the immune system of the CAM begins to develop. Although the immune system responds to the tumor through the infiltration of monocytes and inflammatory cells (avian heterophages), the immune response will not be activated before ED18, allowing the transplantation of xenografts or cells without the risk of rejection [28].

In the CAM model, the molecular expression is comparable to that of mammals. Vascular endothelial growth factor receptor (VEGFR)-2 and -3 and prospero homeobox protein 1 (Prox-1) positively express on lymphatic cells [17]. VEGFR-2 is expressed in both lymphatic and blood vessels, whereas VEGR-3 is specifically expressed in lymphatic vessels [17]. The presence of vascular endothelial growth factor C (VEGF-C) is associated with lymphangiogenesis; it exists in two forms, immature and mature, with the mature form capable of binding to VEGFR-2 in the vascular blood, lymphatic vessels, and differentiated chorioallantoic membrane [29]. It can stimulate lymphatic endothelial cell proliferation and the formation of enlarged lymphatic sinuses [30]. VEGF-A is also present in the CAM, with its secretion peaking twice between ED8–9 and ED11–12 [31, 32]. VEGF-A/hepatocyte growth factor can stimulate the expression of Prox-1 in lymphatic endothelial cells [33]. After 2 weeks of incubation, most growth factors on the CAM reach a peak [33]. Fibroblast growth factor-2 is another endogenous cytokine that promotes angiogenesis, appearing at ED6–18 and peaking at ED10–14 during the chick development [34]. Hypoxia-inducible factor 1 alpha, VEGF, and VEGFR-2 have the highest expression on ED11, which is also associated with the peak in angiogenesis [35, 36].

Angiogenesis is essential for tumor growth, facilitating the supply of nutrients and oxygen, transportation of metabolic waste, and migration to distant sites. The structure of the CAM fosters a microenvironment for tumor development [37]. During the first few days after a potential xenograft transplantation, the transplanted cells will be nourished by diffusion from the CAM [38]. Tumor growth might become visible without magnification after 2–3 days following transplantation [15]. The detailed process of xenograft transplantation is described in Figure 2.

Fig. 2.

Flowchart illustrating tumor growth on the CAM membrane.

Fig. 2.

Flowchart illustrating tumor growth on the CAM membrane.

Close modal

Various compounds and growth factors can stimulate or inhibit angiogenesis on the CAM, and transplanted tumors undergo approximately 72 h of angiogenesis before tumor invasion [16]. The vascular reaction related to the graft occurred 72–96 h after transplantation. Due to the increased density of blood vessels surrounding the implant, the vascular reaction appears as blood vessels converge toward the implant’s center in a “spoke-wheel” pattern [16]. During the development of blood vessels, the mass and volume of the tumor grow rapidly, and necrosis of the tumor center will occur if the new blood vessels cannot support the maturation of the tumor [39]. Tumor blood vessels exhibit abnormal structures, with dilation, chaotic and uneven distribution, and irregular branching, in contrast to normal vessels [40]. Scaffolds such as collagen, Matrigel, and fibrin have been widely used in the CAM assay [41‒43]. Transplanting tumor cells together with the matrix into the CAM is essential for rapid tumor formation because of the vascularization of the scaffold on the CAM membrane.

The CAM model shows practicality in assessing the impact of drugs or tissues on angiogenesis. A series of representative examples exploring angiogenesis using the CAM model is illustrated in Table 1. Furthermore, the CAM model has been used to determine the effect of methylated resveratrol derivatives on angiogenesis, and consistent results are shown regarding the impact on angiogenesis in both the rat aortic ring and the CAM model [44]. The CAM model was also utilized to assess the efficacy of natural curcumin and curcumin-capped copper nanoparticles as potential anticancer and antiangiogenic agents [45]. The relationship between angiogenesis and the tumor microenvironment is studied by Kern et al. [46] on the CAM model. They certified the angiogenesis-inhibiting effect of bortezomib could be antagonized by soluble GRP-78 secreted by certain tumors and demonstrated that solid tumor cells can secrete GRP-78 into the microenvironment of the tumor on the CAM model [46]. The angiogenic potential of tumor tissues can also be validated on the CAM model. Vacca et al. confirmed the potential of lipoma tissue angiogenesis on the CAM model, and the effect of promoting angiogenesis was equivalent to that of fibroblast growth factor-2, confirming that the CAM model is a useful model for this type of research [47]. The CAM model is widely used to investigate the effect of growth factors on antiangiogenesis. The artemisinin derivative FO-ARS-123 acts as a novel VEGFR-2 inhibitor suppressing angiogenesis on the CAM [48]. Rao et al. [49] demonstrated that dihydroartemisinin inhibits angiogenesis in breast cancer on the CAM by regulating VEGF and MMP-2/-9. Methods for quantifying angiogenesis on the CAM primarily include the following techniques [23, 50]:

  • 1.

    Morphometric analysis to measure vascular diameter and length.

  • 2.

    Observation of vascular density using a fluorescent confocal microscope.

  • 3.

    Recording of capillary length, diameter, and density under a scanning electron microscope (Fig. 3).

  • 4.

    Calculation of branch points per square millimeter.

  • 5.

    Observation of blood vessel density on tissue slices.

Table 1.

Key publications of angiogenesis related research on the CAM model

Author, yearInoculation, observation timeTumor type, compoundsMethods
Subauste [42] (2009) ED10, ED12.7–ED13.5 Human SW620 colon carcinoma cell line, type I rat tail collagen The number of grids containing angiogenic blood vessels 
Zhou et al. [51] (2015) ED8, ED10 Cervical cancer (HeLa), cell suspension The number of second and third-order vessels 
Ferician [52] (2015) ED7, ED14 Human renal tumor, tissue fragments IHC to test angiogenic growth factors and vascular network 
Patil [53] (2016) ED5, ED7 Human γδT gallbladder cancer cell line, cell suspension The number of vessels’ branching points 
Valiulytė et al. [54] (2019) ED7, ED12 Human U87 MG glioblastoma cell line, type I rat tail collagen The number of blood vessels bigger than 10 µm 
Author, yearInoculation, observation timeTumor type, compoundsMethods
Subauste [42] (2009) ED10, ED12.7–ED13.5 Human SW620 colon carcinoma cell line, type I rat tail collagen The number of grids containing angiogenic blood vessels 
Zhou et al. [51] (2015) ED8, ED10 Cervical cancer (HeLa), cell suspension The number of second and third-order vessels 
Ferician [52] (2015) ED7, ED14 Human renal tumor, tissue fragments IHC to test angiogenic growth factors and vascular network 
Patil [53] (2016) ED5, ED7 Human γδT gallbladder cancer cell line, cell suspension The number of vessels’ branching points 
Valiulytė et al. [54] (2019) ED7, ED12 Human U87 MG glioblastoma cell line, type I rat tail collagen The number of blood vessels bigger than 10 µm 
Fig. 3.

In vivo CAM images and in silico CAM capillary network contours. Validate and quantify the effects of control, VEGF 50 ng, and VEGF 100 ng on angiogenesis. Images adapted from Guerra et al. [50] (permission by Elsevier and Copyright Clearance Center [5761730824132]).

Fig. 3.

In vivo CAM images and in silico CAM capillary network contours. Validate and quantify the effects of control, VEGF 50 ng, and VEGF 100 ng on angiogenesis. Images adapted from Guerra et al. [50] (permission by Elsevier and Copyright Clearance Center [5761730824132]).

Close modal

Additionally, scientific approaches for quantifying angiogenesis include counting the number of capillaries and the number of blood vessels growing into the collagen matrix [55]. The use of μCT for three-dimensional vascular remodeling is another method employed [56, 57]. The ex oxo and in ovo three-dimensional vascular remodeling picture are depicted in Figure 4.

Fig. 4.

3D imaging of the vascular network within egg embryos using μCT. a Chick embryo with intravascular injection of barium contrast agent. Surface (b), depth (c), and depth 3D reconstructed (d) images by μCT. e Clinical digital mammographic unit. f–h 2D digital microangiography views. i Microscopic view of H&E staining picture. V: major CAM blood vessel; small red arrows: chorion capillaries. Images adapted from Chen et al. [57] (permission by Elsevier and Copyright Clearance Center [5761670236733]).

Fig. 4.

3D imaging of the vascular network within egg embryos using μCT. a Chick embryo with intravascular injection of barium contrast agent. Surface (b), depth (c), and depth 3D reconstructed (d) images by μCT. e Clinical digital mammographic unit. f–h 2D digital microangiography views. i Microscopic view of H&E staining picture. V: major CAM blood vessel; small red arrows: chorion capillaries. Images adapted from Chen et al. [57] (permission by Elsevier and Copyright Clearance Center [5761670236733]).

Close modal

CAM from nontumoral tissue can also be utilized for chemical studies, such as the determination of DNA, protein, and collagen content, as well as reverse transcription-polymerase chain reaction analysis of gene expression in transplanting cells [58]. Histological examinations, including hematoxylin and eosin staining and immunohistochemical staining with CD31 antibody or von Willebrand factor, are common analyses employed to identify sprouting or de novo-generated vessels [51, 59].

Lymphangiogenesis, or its absence, is associated with numerous pathological conditions such as cancer metastasis, lymphedema, and organ transplant rejection [3, 60‒62]. The high incidence of lymphatic metastasis is closely linked to poor prognosis and high mortality in cancer patients [3]. Effective inhibitors are urgently needed to prevent pathological lymphangiogenesis and lymphatic cancerous spread. Clinical evidence suggests that lymphatic vessels contribute to cancer cell dissemination 3–5 times more than blood vessels [63]. This phenomenon can be attributed to lymphatic vessel dilation, which facilitates both the infiltration and extravasation of tumor cells, thereby promoting their survival [63].

Multiple in vitro and in vivo techniques have been employed to study the pharmacological regulation of lymphangiogenesis [64]. In vitro culture systems have been developed for the formation of lymphatic vessels, including in vitro culture of lymphatic endothelial cells obtained from Freund’s adjuvant, thoracic duct fragment explants, embryoid bodies, and immune-purified primary or immortalized human dermal cells [65]. The aortic ring assay is used for testing the molecular mechanisms of angiogenesis [66], investigating genetically modification of mouse lines [67], and evaluating the effect of pro- and antiangiogenic agents [68]. Further, the aortic ring assay has been used as a platform for the lymphatic capillary-like sprouting that can be quantified via supplementary imaging of lymphangiogenesis [65]. While these models are useful for studying cell proliferation and migration, their ability to simulate lymphangiogenesis is limited due to the inability to accurately replicate the complex system of growth factors, stabilizing niches, and regulatory factors that contribute to lymphoid growth [65, 69].

Various preclinical models have been developed to investigate lymphangiogenesis and lymphatic dysfunction, providing a better microenvironment for multifactorial diseases [70, 71]. In vivo models of lymphangiogenesis mainly include overexpression of VEGF-C in tumor cells or transgenic mice to induce lymphangiogenesis [72, 73], intraperitoneal injection Freund’s adjuvant reagent to promote lymphangiogenesis in murine models [74, 75], and resection or microsurgery to cutoff mouse lymphatic vessels in the tail [76]. The mouse tail model was developed further to test the efficacy of tacrolimus and identify potential mechanisms for treating lymphedema [77]. Doh et al. [78] developed a fluorescent reporter transgenic mouse model for live in vivo imaging of lymphangiogenesis. A standard model of lower limb lymphedema in rats was established, certifying that the combination of inguinal lymph node dissection, peripheral skin, and subcutaneous tissue resection is translationally sufficient, and no radiotherapy is necessary [79]. Another lymphedema model in rabbits was established by microsurgically transferring lymph nodes without transferring lymph vessels or cells, validating this model as a reliable tool for refining microsurgical techniques for lymphedema surgeries [80]. However, a limitation of using these models is the inflammatory response, making it difficult to distinguish whether the formation of lymphatic vessels is directly affected by lymphatic endothelial cells or indirectly affected by the production of inflammatory mediators [65].

The CAM model is also a valuable preclinical model for lymphangiogenesis experiments, particularly those involving immune cell trafficking, transplantation, therapeutic responses, and metastasis [30, 81‒84]. However, many studies examining lymphangiogenesis using the CAM model remain highly limited. Table 2 summarizes representative tumor metastasis experimentation on the CAM model.

Table 2.

Key publications of lymphangiogenesis related research on the CAM model

Author, yearInoculation, observation timeTumor type, compoundsMethods
Papoutsi et al. [85] (2001) ED8 and ED10, ED14–17 Rat C6 glioma and 10AS pancreatic carcinoma cells, cell suspension 1. Protein expression of lymphatic marker (immunohistochemistry for α-SMA) 
2. Gene expression of lymphatic vessel growth regulator (Northern blot analysis of VEGF-C and -D) 
3. Lymphatics within tumor (VEGFR-3/Quek2 in situ hybridization) 
Deryugina [86] (2005) ED10, ED11–16 Human HT-1080 fibrosarcoma cell line, cell suspension injection Lymphatic metastasize potential from the primary tumor (assessing tumor invasiveness via metastasis from chorionic vessels to lungs by Alu PCR, Immunohistochemistry for murine mAb 29-7) 
Subauste et al. [42] (2009) ED12, ED15 Human SW620 colon carcinoma cell line and SW480 cell variant, cell suspension injection 1. Live cell imaging for cell extravasation from CAM vessels (cell tracker CMFDA) 
2. Assessing cell colonization in CAM and visceral organs (liver, spleen, lungs) by Alu qPCR 
3. Colon cancer cell colonization on the CAM (immunohistochemistry for antihuman pan-cytokeratin monoclonal antibodies) 
Lokman et al. [43] (2012) ED11, ED14 Human OVCAR-3, SKOV-3, and OV-90 ovarian cancer cell lines, Matrigel Ovarian cancer cell invasion on the CAM (immunohistochemistry for antihuman cytokeratin clone AE1/AE3) 
Author, yearInoculation, observation timeTumor type, compoundsMethods
Papoutsi et al. [85] (2001) ED8 and ED10, ED14–17 Rat C6 glioma and 10AS pancreatic carcinoma cells, cell suspension 1. Protein expression of lymphatic marker (immunohistochemistry for α-SMA) 
2. Gene expression of lymphatic vessel growth regulator (Northern blot analysis of VEGF-C and -D) 
3. Lymphatics within tumor (VEGFR-3/Quek2 in situ hybridization) 
Deryugina [86] (2005) ED10, ED11–16 Human HT-1080 fibrosarcoma cell line, cell suspension injection Lymphatic metastasize potential from the primary tumor (assessing tumor invasiveness via metastasis from chorionic vessels to lungs by Alu PCR, Immunohistochemistry for murine mAb 29-7) 
Subauste et al. [42] (2009) ED12, ED15 Human SW620 colon carcinoma cell line and SW480 cell variant, cell suspension injection 1. Live cell imaging for cell extravasation from CAM vessels (cell tracker CMFDA) 
2. Assessing cell colonization in CAM and visceral organs (liver, spleen, lungs) by Alu qPCR 
3. Colon cancer cell colonization on the CAM (immunohistochemistry for antihuman pan-cytokeratin monoclonal antibodies) 
Lokman et al. [43] (2012) ED11, ED14 Human OVCAR-3, SKOV-3, and OV-90 ovarian cancer cell lines, Matrigel Ovarian cancer cell invasion on the CAM (immunohistochemistry for antihuman cytokeratin clone AE1/AE3) 

α-SMA, alpha-smooth muscle actin.

Oh et al. [25] described the structure of lymphatic vessels on the CAM model and confirmed that VEGF and VEGF-C can promote angiogenesis and lymphangiogenesis in the chick embryo. In a further translational step, the mechanisms underlying melanoma metastasis and tumor lymphatic vessel formation were comprehensively characterized [87]. The VEGF-C/flt4 interaction, crucial for tumor-associated lymphatic vessel formation, has been confirmed in the CAM model by Papoutsi et al. [88]. Others examined C6 glioma (low expression of VEGF-C) and 10AS pancreatic carcinoma (high expression of VEGF-C) in this model and found that 10AS can stimulate lymphangiogenesis [85]. This demonstrated that the lymphatic spreading of cancer is an interspecies conserved pathomechanisms and the in vivo lymphangiogenesis in the CAM of tumoral xenograft-derived lymphangiogenic factors [85]. Cimpean et al. [32] demonstrated that the angiogenesis-promoting cytokines VEGF-A and hepatocyte growth factor not only promote the expression of blood vessels in the CAM but also the expression of Prox-1-positive lymphatic endothelial cells. The dual effects of everolimus on lymphatic vessels and the potential effects of the drug on lymphangiogenesis were also confirmed in this model [89]. Klingenberg used the CAM model as the xenograft model of Burkitt lymphoma to study real-time lymphatic metastasis, confirming that CAM can be used as a tool for studying real-time lymphatic metastasis [90].

Like in angiogenesis, the CAM model can also serve as a valuable model for studying lymphangiogenesis. However, the full potential of in vivo studies of lymphangiogenesis in this model has not been realized due to the lack of specific antibodies against chick embryo antigenic determinants.

The formation of blood vessels and lymphatic vessels is a dynamic process that depends not only on the regulation of endothelial cells of the microvasculature and perivascular lymphatic cells but also on hemodynamics, the microenvironment, and growth factors [4]. The CAM model has been effectively utilized to investigate the proliferation, migration, and differentiation of endothelial cells, as well as the observation and analysis of tumor-induced angiogenesis and metastasis [82]. It has also been valuable for studying the provascular or anti-vascular effects of pharmacological compounds and for the development of translational tissue engineering [23]. However, current research on lymphatic vessels in CAM models, such as immune cell trafficking, graft rejection, and metastasis of tumor through the lymphatic vessels, is still limited. With extensive research on lymphatic vessels, we anticipate a great ability to test the inhibitory effect of related drugs on blood vessels and lymphatic vessels via the allantoic membrane of chicken embryos or to use this model to hinder the blood and lymphatic metastasis of related tumors.

Compared to conventional animal models, the CAM model requires only 2–5 days following cell suspension to observe tumor growth that can be monitored throughout the entire embryological development of the chick [15, 30]. It offers the advantages of a short cycle time, simple operation, and low cost [23]. However, CAM models still have limitations. There are few specific antibodies against antigenic determinants of chicken lymphatic vessels, and it is difficult to distinguish between the angiogenesis and lymphangiogenesis secondary to the graft and the blood vessels and lymphatic vessels of the model itself [85]. Obtaining experimental results is hampered by the growth and development of chicken embryos, the short time window for observation and treatment, and species-specific differences. For instance, oxygen diffuses into the blood vessels and surrounding tissues on the CAM surface, whereas in vivo mammalian tumor models and clinical cases frequently experience severe hypoxia, which can promote metastatic progression. In in vivo mammalian models, tumors generally arise within the tissue or organ of the host, providing an environment that more closely mimics the native tumor microenvironment found in humans. Nevertheless, CAM models are the most accessible and reliable preclinical platforms for studying angiogenesis and lymphangiogenesis related to various oncological conditions [82, 54].

The CAM model exhibits remarkable advantages in detecting the effects of drugs on tumor lymphatic and blood vessel formation [20]. It can serve as a bridge between in vitro experiments and mammalian studies, facilitating rapid and high-throughput screening of drug efficacy. In the future, with the development of chicken-specific antibodies, the CAM is a poised preclinical model to play a greater role in researching angiogenesis and lymphangiogenesis.

The authors have no conflicts of interest to declare.

No funding was received for this research.

Z.Z.W. drafted the manuscript, created figures and tables, and edited the manuscript. P.A.W. reviewed the manuscript and made important intellectual contributions. C.H., F.F., and A.D. approved the final version of the manuscript.

1.
Garcia
J
,
Hurwitz
HI
,
Sandler
AB
,
Miles
D
,
Coleman
RL
,
Deurloo
R
, et al
.
Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook
.
Cancer Treat Rev
.
2020
;
86
:
102017
.
2.
Papachristos
A
,
Sivolapenko
GB
.
Pharmacogenomics, pharmacokinetics and circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review
.
J Pers Med
.
2020
;
10
(
3
):
79
.
3.
Alitalo
K
.
The lymphatic vasculature in disease
.
Nat Med
.
2011
;
17
(
11
):
1371
80
.
4.
Leong
SP
,
Naxerova
K
,
Keller
L
,
Pantel
K
,
Witte
M
.
Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels
.
Clin Exp Metastasis
.
2022
;
39
(
1
):
159
79
.
5.
Xu
W
,
Harris
NR
,
Caron
KM
.
Lymphatic vasculature: an emerging therapeutic target and drug delivery route
.
Annu Rev Med
.
2021
;
72
:
167
82
.
6.
Cheluvappa
R
,
Scowen
P
,
Eri
R
.
Ethics of animal research in human disease remediation, its institutional teaching; and alternatives to animal experimentation
.
Pharmacol Res Perspect
.
2017
;
5
(
4
):
e00332
.
7.
Wang
X
,
Copmans
D
,
de Witte
PAM
.
Using zebrafish as a disease model to study fibrotic disease
.
Int J Mol Sci
.
2021
;
22
(
12
):
6404
.
8.
Tannenbaum
J
,
Bennett
BT
.
Russell and Burch’s 3Rs then and now: the need for clarity in definition and purpose
.
J Am Assoc Lab Anim Sci
.
2015
;
54
(
2
):
120
32
.
9.
Miebach
L
,
Berner
J
,
Bekeschus
S
.
In ovo model in cancer research and tumor immunology
.
Front Immunol
.
2022
;
13
:
1006064
.
10.
Ausprunk
DH
,
Knighton
DR
,
Folkman
J
.
Differentiation of vascular endothelium in the chick chorioallantois: a structural and autoradiographic study
.
Dev Biol
.
1974
;
38
(
2
):
237
48
.
11.
Kurz
H
,
Ambrosy
S
,
Wilting
J
,
Marme
D
,
Christ
B
.
Proliferation pattern of capillary endothelial cells in chorioallantoic membrane development indicates local growth control, which is counteracted by vascular endothelial growth factor application
.
Dev Dyn
.
1995
;
203
(
2
):
174
86
.
12.
Ausprunk
DH
.
Distribution of hyaluronic acid and sulfated glycosaminoglycans during blood-vessel development in the chick chorioallantoic membrane
.
Am J Anat
.
1986
;
177
(
3
):
313
31
.
13.
Jacoby
DB
,
Dyskin
E
,
Yalcin
M
,
Kesavan
K
,
Dahlberg
W
,
Ratliff
J
, et al
.
Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide
.
Anticancer Res
.
2010
;
30
(
1
):
39
46
.
14.
Farina
HG
,
Benavent Acero
F
,
Perera
Y
,
Rodriguez
A
,
Perea
SE
,
Castro
BA
, et al
.
CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo
.
Exp Cell Res
.
2011
;
317
(
12
):
1677
88
.
15.
Ribatti
D
.
The chick embryo chorioallantoic membrane as a model for tumor biology
.
Exp Cell Res
.
2014
;
328
(
2
):
314
24
.
16.
Ribatti
D
.
The chick embryo chorioallantoic membrane (CAM). A multifaceted experimental model
.
Mech Dev
.
2016
;
141
:
70
7
.
17.
Wilting
J
,
Birkenhager
R
,
Eichmann
A
,
Kurz
H
,
Martiny-Baron
G
,
Marme
D
, et al
.
VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane
.
Dev Biol
.
1996
;
176
(
1
):
76
85
.
18.
Papoutsi
M
,
Tomarev
SI
,
Eichmann
A
,
Prols
F
,
Christ
B
,
Wilting
J
.
Endogenous origin of the lymphatics in the avian chorioallantoic membrane
.
Dev Dyn
.
2001
;
222
(
2
):
238
51
.
19.
Vilches-Moure
JG
.
Embryonic chicken (Gallus gallus domesticus) as a model of cardiac biology and development
.
Comp Med
.
2019
;
69
(
3
):
184
203
.
20.
Ribatti
D
.
The chick embryo chorioallantoic membrane as an experimental model to study in vivo angiogenesis in glioblastoma multiforme
.
Brain Res Bull
.
2022
;
182
:
26
9
.
21.
DeFouw
DO
,
Rizzo
VJ
,
Steinfeld
R
,
Feinberg
RN
.
Mapping of the microcirculation in the chick chorioallantoic membrane during normal angiogenesis
.
Microvasc Res
.
1989
;
38
(
2
):
136
47
.
22.
Rezzola
S
,
Loda
A
,
Corsini
M
,
Semeraro
F
,
Annese
T
,
Presta
M
, et al
.
Angiogenesis-inflammation cross talk in diabetic retinopathy: novel insights from the chick embryo chorioallantoic membrane/human vitreous platform
.
Front Immunol
.
2020
;
11
:
581288
.
23.
Ribatti
D
.
The chick embryo chorioallantoic membrane (CAM) assay
.
Reprod Toxicol
.
2017
;
70
:
97
101
.
24.
Auerbach
R
,
Kubai
L
,
Knighton
D
,
Folkman
J
.
A simple procedure for the long-term cultivation of chicken embryos
.
Dev Biol
.
1974
;
41
(
2
):
391
4
.
25.
Oh
SJ
,
Jeltsch
MM
,
Birkenhager
R
,
McCarthy
JE
,
Weich
HA
,
Christ
B
, et al
.
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
.
Dev Biol
.
1997
;
188
(
1
):
96
109
.
26.
Clark
ER
.
Technique of operating on chick embryos
.
Science
.
1920
;
51
(
1319
):
371
3
.
27.
Parsons-Wingerter
P
,
McKay
TL
,
Leontiev
D
,
Vickerman
MB
,
Condrich
TK
,
Dicorleto
PE
.
Lymphangiogenesis by blind-ended vessel sprouting is concurrent with hemangiogenesis by vascular splitting
.
Anat Rec A Discov Mol Cell Evol Biol
.
2006
;
288
(
3
):
233
47
.
28.
Tay
H
,
Du Cheyne
C
,
Demeyere
K
,
De Craene
J
,
De Bels
L
,
Meyer
E
, et al
.
Depletion of embryonic macrophages leads to a reduction in angiogenesis in the ex ovo chick chorioallantoic membrane assay
.
Cells
.
2020
;
10
(
1
):
5
.
29.
Wilting
J
,
Christ
B
.
Embryonic angiogenesis: a review
.
Naturwissenschaften
.
1996
;
83
(
4
):
153
64
.
30.
Nowak-Sliwinska
P
,
Segura
T
,
Iruela-Arispe
ML
.
The chicken chorioallantoic membrane model in biology, medicine and bioengineering
.
Angiogenesis
.
2014
;
17
(
4
):
779
804
.
31.
Baum
O
,
Suter
F
,
Gerber
B
,
Tschanz
SA
,
Buergy
R
,
Blank
F
, et al
.
VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane
.
Microcirculation
.
2010
;
17
(
6
):
447
57
.
32.
Cimpean
AM
,
Seclaman
E
,
Ceauşu
R
,
Gaje
P
,
Feflea
S
,
Anghel
A
, et al
.
VEGF-A/HGF induce Prox-1 expression in the chick embryo chorioallantoic membrane lymphatic vasculature
.
Clin Exp Med
.
2010
;
10
(
3
):
169
72
.
33.
Alkie
TN
,
Yitbarek
A
,
Hodgins
DC
,
Kulkarni
RR
,
Taha-Abdelaziz
K
,
Sharif
S
.
Development of innate immunity in chicken embryos and newly hatched chicks: a disease control perspective
.
Avian Pathol
.
2019
;
48
(
4
):
288
310
.
34.
Ribatti
D
,
Urbinati
C
,
Nico
B
,
Rusnati
M
,
Roncali
L
,
Presta
M
.
Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane
.
Dev Biol
.
1995
;
170
(
1
):
39
49
.
35.
Marinaccio
C
,
Nico
B
,
Ribatti
D
.
Differential expression of angiogenic and anti-angiogenic molecules in the chick embryo chorioallantoic membrane and selected organs during embryonic development
.
Int J Dev Biol
.
2013
;
57
(
11–12
):
907
16
.
36.
Makanya
AN
,
Dimova
I
,
Koller
T
,
Styp-Rekowska
B
,
Djonov
V
.
Dynamics of the developing chick chorioallantoic membrane assessed by stereology, allometry, immunohistochemistry and molecular analysis
.
PLoS One
.
2016
;
11
(
4
):
e0152821
.
37.
Jackson
CE
,
Doyle
I
,
Khan
H
,
Williams
SF
,
Aldemir Dikici
B
,
Barajas Ledesma
E
, et al
.
Gelatin-containing porous polycaprolactone PolyHIPEs as substrates for 3D breast cancer cell culture and vascular infiltration
.
Front Bioeng Biotechnol
.
2023
;
11
:
1321197
.
38.
Balciuniene
N
,
Tamasauskas
A
,
Valanciute
A
,
Deltuva
V
,
Vaitiekaitis
G
,
Gudinaviciene
I
, et al
.
Histology of human glioblastoma transplanted on chicken chorioallantoic membrane
.
Med Kaunas
.
2009
;
45
(
2
):
123
31
.
39.
Knighton
D
,
Ausprunk
D
,
Tapper
D
,
Folkman
J
.
Avascular and vascular phases of tumour growth in the chick embryo
.
Br J Cancer
.
1977
;
35
(
3
):
347
56
.
40.
Nagy
JA
,
Chang
SH
,
Shih
SC
,
Dvorak
AM
,
Dvorak
HF
.
Heterogeneity of the tumor vasculature
.
Semin Thromb Hemost
.
2010
;
36
(
3
):
321
31
.
41.
Borges
J
,
Tegtmeier
FT
,
Torio-Padron
N
,
Mueller
MC
,
Stark
GB
.
Untersuchung der Angiogenese im Tissue Engineering
.
Chirurg
.
2004
;
75
(
3
):
284
90
.
42.
Subauste
MC
,
Kupriyanova
TA
,
Conn
EM
,
Ardi
VC
,
Quigley
JP
,
Deryugina
EI
.
Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems
.
Clin Exp Metastasis
.
2009
;
26
(
8
):
1033
47
.
43.
Lokman
NA
,
Elder
ASF
,
Ricciardelli
C
,
Oehler
MK
.
Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis
.
Int J Mol Sci
.
2012
;
13
(
8
):
9959
70
.
44.
Chen
Z
,
Zhang
L
,
Yu
J
,
Chen
L
,
Zhou
B
.
Identification of resveratrol derivative 3,3',4,4',5,5'-hexamethoxy- trans-stilbene as a novel pro-angiogenic small-molecule compound
.
Eur J Pharmacol
.
2016
;
791
:
185
94
.
45.
Kamble
S
,
Utage
B
,
Mogle
P
,
Kamble
R
,
Hese
S
,
Dawane
B
, et al
.
Evaluation of curcumin capped copper nanoparticles as possible inhibitors of human breast cancer cells and angiogenesis: a comparative study with native curcumin
.
AAPS PharmSciTech
.
2016
;
17
(
5
):
1030
41
.
46.
Kern
J
,
Untergasser
G
,
Zenzmaier
C
,
Sarg
B
,
Gastl
G
,
Gunsilius
E
, et al
.
GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib
.
Blood
.
2009
;
114
(
18
):
3960
7
.
47.
Lucarelli
E
,
Sangiorgi
L
,
Benassi
S
,
Donati
D
,
Gobbi
GA
,
Picci
P
, et al
.
Angiogenesis in lipoma: an experimental study in the chick embryo chorioallantoic membrane
.
Int J Mol Med
.
1999
;
4
(
6
):
593
6
.
48.
Lu
X
,
Elbadawi
M
,
Blatt
S
,
Saeed
MEM
,
Xiao
X
,
Ma
X
, et al
.
Artemisinin derivative FO-ARS-123 as a novel VEGFR2 inhibitor suppresses angiogenesis, cell migration, and invasion
.
Chem Biol Interact
.
2022
;
365
:
110062
.
49.
Rao
Q
,
Yu
H
,
Li
R
,
He
B
,
Wang
Y
,
Guo
X
, et al
.
Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9
.
Fundam Clin Pharmacol
.
2024
;
38
(
1
):
113
25
.
50.
Guerra
A
,
Belinha
J
,
Mangir
N
,
MacNeil
S
,
Natal Jorge
R
.
Simulation of the process of angiogenesis: quantification and assessment of vascular patterning in the chicken chorioallantoic membrane
.
Comput Biol Med
.
2021
;
136
:
104647
.
51.
Kleibeuker
EA
,
Ten Hooven
MA
,
Castricum
KC
,
Honeywell
R
,
Griffioen
AW
,
Verheul
HM
, et al
.
Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
.
Cancer Med
.
2015
;
4
(
7
):
1003
15
.
52.
Ferician
O
,
Cimpean
AM
,
Avram
S
,
Raica
M
.
Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane
.
Anticancer Res
.
2015
;
35
(
12
):
6521
8
.
53.
Patil
RS
,
Shah
SU
,
Shrikhande
SV
,
Goel
M
,
Dikshit
RP
,
Chiplunkar
SV
.
IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients
.
Int J Cancer
.
2016
;
139
(
4
):
869
81
.
54.
Valiulyte
I
,
Curkunaviciute
R
,
Ribokaite
L
,
Kazlauskas
A
,
Vaitkeviciute
M
,
Skauminas
K
, et al
.
The anti-tumorigenic activity of Sema3C in the chick embryo chorioallantoic membrane model
.
Int J Mol Sci
.
2019
;
20
(
22
):
5672
.
55.
Sun
F
,
Lu
Y
,
Wang
Z
,
Zhang
B
,
Shen
Z
,
Yuan
L
, et al
.
Directly construct microvascularization of tissue engineering trachea in orthotopic transplantation
.
Mater Sci Eng C Mater Biol Appl
.
2021
;
128
:
112201
.
56.
Otto
L
,
Wolint
P
,
Bopp
A
,
Woloszyk
A
,
Becker
AS
,
Boss
A
, et al
.
3D-microtissue derived secretome as a cell-free approach for enhanced mineralization of scaffolds in the chorioallantoic membrane model
.
Sci Rep
.
2021
;
11
(
1
):
5418
.
57.
Chen
L
,
Wang
S
,
Feng
Y
,
Yu
J
,
Coudyzer
W
,
Van Ongeval
C
, et al
.
Development and characterization of a chick embryo chorioallantoic membrane (CAM) based platform for evaluation of vasoactive medications
.
Microvasc Res
.
2022
;
142
:
104372
.
58.
Patel
SA
,
Hassan
MK
,
Naik
M
,
Mohapatra
N
,
Balan
P
,
Korrapati
PS
, et al
.
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia
.
Br J Cancer
.
2024
;
130
(
2
):
184
200
.
59.
Ames
JJ
,
Henderson
T
,
Liaw
L
,
Brooks
PC
.
Methods for analyzing tumor angiogenesis in the chick chorioallantoic membrane model
.
Methods Mol Biol
.
2016
;
1406
:
255
69
.
60.
Wang
Y
,
Oliver
G
.
Current views on the function of the lymphatic vasculature in health and disease
.
Genes Dev
.
2010
;
24
(
19
):
2115
26
.
61.
Miyazaki
H
,
Yoshimatsu
Y
,
Akatsu
Y
,
Mishima
K
,
Fukayama
M
,
Watabe
T
, et al
.
Expression of platelet-derived growth factor receptor β is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis
.
Cancer Sci
.
2014
;
105
(
9
):
1116
23
.
62.
Yang
JF
,
Walia
A
,
Huang
YH
,
Han
KY
,
Rosenblatt
MI
,
Azar
DT
, et al
.
Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions
.
Surv Ophthalmol
.
2016
;
61
(
3
):
272
96
.
63.
Chen
SM
,
Zhao
CK
,
Yao
LC
,
Wang
LX
,
Ma
YN
,
Meng
L
, et al
.
Aiphanol, a multi-targeting stilbenolignan, potently suppresses mouse lymphangiogenesis and lymphatic metastasis
.
Acta Pharmacol Sin
.
2023
;
44
(
1
):
189
200
.
64.
Bruyere
F
,
Noel
A
.
Lymphangiogenesis: in vitro and in vivo models
.
FASEB J
.
2010
;
24
(
1
):
8
21
.
65.
Bruyere
F
,
Melen-Lamalle
L
,
Blacher
S
,
Roland
G
,
Thiry
M
,
Moons
L
, et al
.
Modeling lymphangiogenesis in a three-dimensional culture system
.
Nat Methods
.
2008
;
5
(
5
):
431
7
.
66.
Nicosia
RF
,
Ottinetti
A
.
Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro
.
Lab Invest
.
1990
;
63
(
1
):
115
22
.
67.
Masson V
,
Devy
L
,
Grignet-Debrus
C
,
Bernt
S
,
Bajou
K
,
Blacher
S
, et al
.
Mouse aortic ring assay: a new approach of the molecular genetics of angiogenesis
.
Biol Proced Online
.
2002
;
4
:
24
31
.
68.
Maquoi
E
,
Sounni
NE
,
Devy
L
,
Olivier
F
,
Frankenne
F
,
Krell
HW
, et al
.
Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor
.
Clin Cancer Res
.
2004
;
10
(
12 Pt 1
):
4038
47
.
69.
Ud-Din
S
,
Bayat
A
.
Non-animal models of wound healing in cutaneous repair: in silico, in vitro, ex vivo, and in vivo models of wounds and scars in human skin
.
Wound Repair Regen
.
2017
;
25
(
2
):
164
76
.
70.
Eklund
L
,
Bry
M
,
Alitalo
K
.
Mouse models for studying angiogenesis and lymphangiogenesis in cancer
.
Mol Oncol
.
2013
;
7
(
2
):
259
82
.
71.
Ruliffson
BNK
,
Whittington
CF
.
Regulating lymphatic vasculature in fibrosis: understanding the biology to improve the modeling
.
Adv Biol
.
2023
;
7
(
5
):
e2200158
.
72.
Mandriota
SJ
,
Jussila
L
,
Jeltsch
M
,
Compagni
A
,
Baetens
D
,
Prevo
R
, et al
.
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
.
EMBO J
.
2001
;
20
(
4
):
672
82
.
73.
Skobe
M
,
Hawighorst
T
,
Jackson
DG
,
Prevo
R
,
Janes
L
,
Velasco
P
, et al
.
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
.
Nat Med
.
2001
;
7
(
2
):
192
8
.
74.
Mancardi
S
,
Stanta
G
,
Dusetti
N
,
Bestagno
M
,
Jussila
L
,
Zweyer
M
, et al
.
Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund’s adjuvant
.
Exp Cell Res
.
1999
;
246
(
2
):
368
75
.
75.
Nakamura
ES
,
Koizumi
K
,
Kobayashi
M
,
Saiki
I
.
Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270
.
Cancer Sci
.
2004
;
95
(
1
):
25
31
.
76.
Tabibiazar
R
,
Cheung
L
,
Han
J
,
Swanson
J
,
Beilhack
A
,
An
A
, et al
.
Inflammatory manifestations of experimental lymphatic insufficiency
.
PLoS Med
.
2006
;
3
(
7
):
e254
.
77.
Gardenier
JC
,
Kataru
RP
,
Hespe
GE
,
Savetsky
IL
,
Torrisi
JS
,
Nores
GD
, et al
.
Topical tacrolimus for the treatment of secondary lymphedema
.
Nat Commun
.
2017
;
8
:
14345
.
78.
Doh
SJ
,
Yamakawa
M
,
Santosa
SM
,
Montana
M
,
Guo
K
,
Sauer
JR
, et al
.
Fluorescent reporter transgenic mice for in vivo live imaging of angiogenesis and lymphangiogenesis
.
Angiogenesis
.
2018
;
21
(
4
):
677
98
.
79.
Harb
AA
,
Levi
MA
,
Corvi
JJ
,
Nicolas
CF
,
Zheng
Y
,
Chaudhary
KR
, et al
.
Creation of a rat lower limb lymphedema model
.
Ann Plast Surg
.
2020
;
85
(
S1 Suppl 1
):
S129
34
.
80.
Fernández Peñuela
R
,
Casani Arazo
L
,
Masia Ayala
J
.
Outcomes in vascularized lymph node transplantation in rabbits: a reliable model for improving the surgical approach to lymphedema
.
Lymphat Res Biol
.
2019
;
17
(
4
):
413
7
.
81.
Deryugina
EI
,
Quigley
JP
.
Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules
.
Methods Enzymol
.
2008
;
444
:
21
41
.
82.
Herrmann
A
,
Moss
D
,
See
V
.
The chorioallantoic membrane of the chick embryo to assess tumor formation and metastasis
.
Methods Mol Biol
.
2016
;
1464
:
97
105
.
83.
Javed
S
,
Soukhtehzari
S
,
Fernandes
N
,
Williams
KC
.
Longitudinal bioluminescence imaging to monitor breast tumor growth and treatment response using the chick chorioallantoic membrane model
.
Sci Rep
.
2022
;
12
(
1
):
17192
.
84.
Vatanparast
M
,
Maleki
B
,
Khalili
MA
.
Ischemia and vasculogenesis after transplantation of frozen and vitrified human ovarian tissue onto Chick Embryo Chorioallantoic Membrane (CAM)
.
Eur J Obstet Gynecol Reprod Biol
.
2023
;
284
:
94
9
.
85.
Papoutsi
M
,
Sleeman
JP
,
Wilting
J
.
Interaction of rat tumor cells with blood vessels and lymphatics of the avian chorioallantoic membrane
.
Microsc Res Tech
.
2001
;
55
(
2
):
100
7
.
86.
Deryugina
EI
,
Zijlstra
A
,
Partridge
JJ
,
Kupriyanova
TA
,
Madsen
MA
,
Papagiannakopoulos
T
, et al
.
Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination
.
Cancer Res
.
2005
;
65
(
23
):
10959
69
.
87.
Dani
SU
,
Espindola
R
.
A model system for testing gene vectors using murine tumor cells on the chorioallantoic membrane of the chick embryo
.
Genet Mol Res
.
2002
;
1
(
2
):
167
75
.
88.
Papoutsi
M
,
Siemeister
G
,
Weindel
K
,
Tomarev
SI
,
Kurz
H
,
Schachtele
C
, et al
.
Active interaction of human A375 melanoma cells with the lymphatics in vivo
.
Histochem Cell Biol
.
2000
;
114
(
5
):
373
85
.
89.
Ceausu
RA
,
Cimpean
AM
,
Dimova
I
,
Hlushchuk
R
,
Djonov
V
,
Gaje
PN
, et al
.
Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis
.
In Vivo
.
2013
;
27
(
1
):
61
6
.
90.
Klingenberg
M
,
Becker
J
,
Eberth
S
,
Kube
D
,
Wilting
J
.
The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma
.
BMC Cancer
.
2014
;
14
:
339
.